GlassScriptPhysician profile
Marcy King
NPI 1962853911
$2,843.65
in general payments reported to CMS, 2019-2025
34 companies · $135 in 2025
The $135 reported for 2025 was less than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,241 · 2022: $308 · 2023: $46.29 · 2024: $113 · 2025: $135.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $295.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $294.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $348.08 | 2021-2022 | |
| Novo Nordisk INC | $322.68 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $229.27 | 2024-2025 | Ingrezza |
| Lilly USA, LLC | $182.77 | 2021 | |
| Pfizer INC. | $158.57 | 2021-2023 | |
| Astrazeneca Pharmaceuticals LP | $150.14 | 2021-2022 | |
| Glaxosmithkline, LLC. | $126.76 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $126.32 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $107.88 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $89.83 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $85.65 | 2021-2022 | |
| Astellas Pharma US INC | $85.47 | 2021 | |
| Merck Sharp & Dohme LLC | $80.11 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $75.37 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $61.92 | 2021 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $58.68 | 2021 | |
| Amgen INC. | $56.90 | 2021 | |
| Amarin Pharma, INC. | $45.90 | 2021-2022 | |
| Dexcom, INC. | $44.96 | 2021-2022 | |
| Esperion Therapeutics, INC. | $42.61 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $39.25 | 2021 | |
| Hikma Pharmaceuticals USA | $36.70 | 2021 | |
| Eyevance Pharmaceuticals LLC | $36.70 | 2021 | |
| Eisai INC. | $35.22 | 2021 | |
| Arbor Pharmaceuticals, INC. | $32.84 | 2021 | |
| Boston Scientific Corporation | $32.29 | 2023 | |
| Biohaven Pharmaceuticals, INC. | $31.00 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $25.76 | 2022 | |
| Daiichi Sankyo INC. | $19.93 | 2021 | |
| Clarus Therapeutics INC. | $19.36 | 2021 | |
| Ani Pharmaceuticals, INC. | $19.30 | 2024 | Purified Cortrophin Gel |
| Insulet Corporation | $17.48 | 2021 | |
| Novartis Pharmaceuticals Corporation | $15.70 | 2021 | |
| Genentech USA, INC. | $2.25 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marcy King listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.